Low-pass whole-genome sequencing (LP-WGS) of circulating tumor DNA (ctDNA) is increasingly recognized for its utility in identifying somatic copy-number aberration (CNA). In this study, we analyzed LP-WGS ctDNA data from 73 pediatric patients with neuroblastic tumor and 11 healthy controls to explore diagnostic value of ctDNA CNA burden (including the genotypings) with a customized bioinformatics workflow. We found that a high baseline ctDNA CNA burden [tumor DNA fraction (TFx) ≥0.2%] was present in 36 of 41 patients (87.80%) with neuroblastoma, six of 22 patients (27.27%) with ganglioneuroblastoma, and three of 10 patients (30%) with ganglioneuroma. High baseline ctDNA CNA burden could predict high-risk neuroblastic tumors with an area under curve (AUC) of 0.95, sensitivity of 94.12%, and specificity of 100%. Frequent chromosomal copy-number changes, including chr17q gain, chr7 gain, chr3p loss, and chr11q loss, were found in ctDNA. Gain of chr17q demonstrated the highest diagnostic value with an AUC of 0.92, indicating strong sensitivity and specificity for detecting high-risk neuroblastic tumors. The homologous recombination deficiency score in the high- and intermediate-risk groups was significantly elevated compared with those in the low-/very low–risk group. The TFx levels and segmental alterations significantly decreased in patients with neuroblastic tumor who underwent chemotherapy, from median TFx = 13.82% before treatment to 0.24% after treatment (P < 0.0001). Our findings highlight the effectiveness of LP-WGS ctDNA CNA analysis as a promising approach for diagnosis and risk stratification of pediatric neuroblastic tumors and for monitoring chemotherapy response. Particularly, ctDNA analysis is minimally invasive, rapid, and cost-effective, which could bring additional benefits in pediatric practices. Significance: Our results support the development of ctDNA CNA analysis as a robust and minimally invasive approach for early detection, molecular diagnosis, and risk stratification of peripheral neuroblastic tumors.
19 August 2025 in World Journal of Pediatric Surgery
Background: Robot-assisted surgery is becoming increasingly used in pediatric oncology. The present study aimed to evaluate the feasibility and safety of robotic liver resection (RLR) for hepatic focal nodular hyperplasia (FNH) in children and compare surgical outcomes between RLR and open liver resection (OLR). Methods: Pediatric patients with liver FNH undergoing lesion resection between January 2020 and June 2024 were included in the study. Patient demographics, operative details, postoperative outcomes, and follow-up were recorded and analyzed. Results: A total of 20 patients were included in this study. Twelve patients underwent RLR and eight underwent OLR. In the RLR group, the median age was 93.1 months (range, 28–134 months) with a median weight of 32.4 kg (range, 9.7–80 kg). The median maximum tumor diameter at operation was 62.6 mm (range, 49–80 mm) and the median tumor volume was 94.3 mL (range, 35–254.1 mL). Operative time was 168.5 min (range, 116–245 min), intraoperative blood loss was 23.3 mL (range, 5–50 mL) and the length of postoperative hospital stay was 5.7 days (range, 4–11 days). There was a significant difference ( p <0.05) between the RLR and OLR groups for: age (93.1 months vs. 137.6 months), maximum tumor diameter (62.6 mm vs. 98 mm), tumor volume (94.3 mL vs. 496.2 mL), operative time (168.5 min vs. 281.4 min), blood loss (23.3 mL vs. 288.7 mL), and length of postoperative hospital stay (5.7 days vs. 9.5 days). There was a borderline significant association between surgical approach (RLR/OLR) and fluctuation in the magnitude of Alanine aminotransferase (ALT) (odds ratio=0.004, 95% confidence interval: 0.000 to 1.096, p =0.05). Conclusions: Our initial experience suggested that RLR for hepatic FNH in children was both feasible and safe. Tumors in the RLR group were significantly smaller than the OLR group: it proved possible to excise tumors larger than 250 mL in volume.
Meckel’s diverticulum (MD) is the most common congenital anomaly of the gastrointestinal (GI) tract. The main clinical manifestation of MD in childhood is GI bleeding. However, symptomatic manifestation in the neonatal period is rare.1 Single umbilical artery (SUA) was first reported by Hyrtl in 1870.2 In recent years, SUA has been reported to be a marker for fetal congenital malformations, chromosomal abnormalities, premature birth, and low birth weight, which can lead to severe adverse outcomes. We hereby report two cases of MD perforation in neonates with SUA in the Yiwu Branch of Children’s Hospital, Zhejiang University School of Medicine.
Chemotherapy effectively reduces CNA burden in patients with pNT. A, Log10 of TFx values in 16 paired ctDNA samples collected before and after chemotherapy from the same patients. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. ****, P < 0.0001. B, Representative genome-wide copy-number variation in patients with pNT before (top) and after (bottom) chemotherapy.